Cargando…

Diagnostic Efficacy of PSMA and PSCA mRNAs Combined to PSA in Prostate Cancer Patients

BACKGROUND: Serum Prostate-specific antigen (PSA) has been used for screening and diagnosis of prostate cancer (PCa) but it is burdened by its low accuracy, creating a need for reliable diagnostic markers. Despite prostate-specific membrane antigen (PSMA) and prostate stem cell antigen (PSCA) being...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mahmoud, Mustafa M, Abdel Hamid, Fatma F, Abdelgawad, Iman, Ismail, Abeer, Malash, Ibrahim, Ibrahim, Doaa M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	West Asia Organization for Cancer Prevention 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152839/ https://www.ncbi.nlm.nih.gov/pubmed/36708571 http://dx.doi.org/10.31557/APJCP.2023.24.1.223

Ejemplares similares

PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer
por: Heinrich, Marie-Christine, et al.
Publicado: (2018)

Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology “UniCAR”
por: Feldmann, Anja, et al.
Publicado: (2017)

A Comparison of the Biological Features of Prostate Cancer with (PSA+, PSMA+) Profile according to RKIP
por: Ben Jemaa, Awatef, et al.
Publicado: (2013)

The Correlation between PSCA Expression and Neuroendocrine Differentiation in Prostate Cancer
por: Xiang, Qian, et al.
Publicado: (2020)

Pretest PSA and Restaging PSMA PET/CT Predict Survival in Biochemically Recurrent Prostate Cancer
por: von Eyben, Rie, et al.
Publicado: (2023)

PSA and PSA Kinetics Thresholds for the Presence of (68)Ga-PSMA-11 PET/CT-Detectable Lesions in Patients with Biochemical Recurrent Prostate Cancer
por: Hoffmann, Manuela Andrea, et al.
Publicado: (2020)

Comparison of [(18)F]PSMA-1007 with [(68)Ga]Ga-PSMA-11 PET/CT in Restaging of Prostate Cancer Patients with PSA Relapse
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

Comparison of percentage free PSA, MRI and GaPSMA PET scan for diagnosing cancer prostate in men with PSA between 4 and 20 ng/ml
por: Kumar, Niraj, et al.
Publicado: (2019)

The Impact of PSMA-PET on Oncologic Control in Prostate Cancer Patients Who Experienced PSA Persistence or Recurrence
por: Bianchi, Lorenzo, et al.
Publicado: (2022)

EAU Biochemical Recurrence Risk Classification and PSA Kinetics Have No Value for Patient Selection in PSMA-Radioguided Surgery (PSMA-RGS) for Oligorecurrent Prostate Cancer
por: Falkenbach, Fabian, et al.
Publicado: (2023)

Genetic variation of the PSCA gene (rs2294008) is not associated with the risk of prostate cancer
por: Lee, Il-Seok, et al.
Publicado: (2017)

Optimizing the Preparation Procedure of Recombinant PSCA, as a Practical Biomarker in Prostate Cancer
por: Shahrabi Farahani, Mahboube, et al.
Publicado: (2021)

Metastatic-directed therapy using PSMA-PET/CT at PSA relapse
por: Lilleby, Oscar, et al.
Publicado: (2019)

Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer
por: Gadot, Moran, et al.
Publicado: (2020)

PSCA rs1045531 Polymorphism and the Risk of Prostate Cancer in a Chinese Population Undergoing Prostate Biopsy
por: Zhang, Xuefeng, et al.
Publicado: (2017)

Antihormone treatment differentially regulates PSA secretion, PSMA expression and (68)Ga–PSMA uptake in LNCaP cells
por: Mathy, C. S., et al.
Publicado: (2021)

Dendritic Cell-Directed Vaccination with a Lentivector Encoding PSCA for Prostate Cancer in Mice
por: Xiao, Liang, et al.
Publicado: (2012)

Development and optimization of PSCA-specific CAR T cells for the treatment of bone metastatic prostate cancer
por: Gerdts, Ethan, et al.
Publicado: (2015)

PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml
por: Solomonidou, Nantia, et al.
Publicado: (2023)

Can the Gleason score be predicted in patients with prostate cancer? A dynamic contrast-enhanced MRI, ((68))Ga-PSMA PET/CT, PSA, and PSA-density comparison study
por: Akkaya, Hüseyin, et al.
Publicado: (2023)

Genetic profiling of different phenotypic subsets of breast cancer stem cells (BCSCs) in breast cancer patients
por: Zekri, Abdel-Rahman N., et al.
Publicado: (2022)

Impact of PSCA Variation on Gastric Ulcer Susceptibility
por: Tanikawa, Chizu, et al.
Publicado: (2013)

Impact of PSCA Polymorphisms on the Risk of Duodenal Ulcer
por: Usui, Yoshiaki, et al.
Publicado: (2021)

Prostate stem cell antigen (PSCA) and risk of bladder cancer: linking genotypes to functional mechanisms
por: Mumy, Adam, et al.
Publicado: (2011)

An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors
por: Lepin, Eric J., et al.
Publicado: (2010)

The therapeutic efficacy of I(131)-PSCA-mAb in orthotopic mouse models of prostate cancer
por: Yu, Shengqiang, et al.
Publicado: (2013)

Dual-Modality ImmunoPET/Fluorescence Imaging of Prostate Cancer with an Anti-PSCA Cys-Minibody
por: Tsai, Wenting K, et al.
Publicado: (2018)

What to Trust, PSA or [(68)Ga]Ga-PSMA-11: Learn from Experience
por: Viglialoro, Rita, et al.
Publicado: (2021)

Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
por: Höti, Naseruddin, et al.
Publicado: (2023)

PSCA rs2294008 Polymorphism with Increased Risk of Cancer
por: Geng, Peiliang, et al.
Publicado: (2015)

Correction: Impact of PSCA Variation on Gastric Ulcer Susceptibility
Publicado: (2014)

Usefulness of Total PSA Value in Prostate Diseases Diagnosis
por: Prcic, Alden, et al.
Publicado: (2016)

Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer
por: Zhigang, Zhao, et al.
Publicado: (2004)

Knockdown of PSCA induces EMT and decreases metastatic potentials of the human prostate cancer DU145 cells
por: Kang, Ran, et al.
Publicado: (2016)

Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA
por: Kristiansen, Ilka, et al.
Publicado: (2017)

A Risk Model for Patients with PSA-Only Recurrence (Biochemical Recurrence) Based on PSA and PSMA PET/CT: An Individual Patient Data Meta-Analysis
por: von Eyben, Rie, et al.
Publicado: (2022)

PSCA polymorphisms and gastric cancer susceptibility in an eastern Chinese population
por: Qiu, Li-Xin, et al.
Publicado: (2016)

Exploring the Tumor-Suppressing Potential of PSCA in Pancreatic Ductal Adenocarcinoma
por: Li, Kexin, et al.
Publicado: (2023)

The positivity rate of 68Gallium-PSMA-11 ligand PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer
por: Hoffmann, Manuela A., et al.
Publicado: (2019)

Is there more than meets the eye in PSMA imaging in prostate cancer with PET/MRI? Looking closer at uptake time, correlation with PSA and Gleason score
por: Bogdanovic, Borjana, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_aru3so7f16lvm2tjpvp44llmpt